Abstract: The invention relates to a method for treating HIV-associated immune thrombocytopenic purpura (ITP) which comprises administering to a patient in need of such treatment a therapeutically effective amount of a molecule comprising an amino acid sequence capable of binding to HIV.

Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.

Abstract: A formulation suitable for inducing bone formation contains about 0.5 .mu.g to about 5 mg of transforming growth factor-.beta. and about 140 mg to about 50 g of tricalcium phosphate and excludes a bone morphogenetic cofactor. In another embodiment, the formulation contains about 0.5 .mu.g to 5 mg transforming growth factor-.beta., about 140 mg to 50 g of tricalcium phosphate particles, and an amount of amylopectin ranging from about 01:1 to 1:1 amylopectin:tricalcium phosphate.

Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.

Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.

Abstract: Disclosed are improved methods for the treatment of lung membrane diseases such as respiratory distress syndrome (RDS) or idiopathic RDS, employing compositions including therapeutically effective amounts of gamma interferon and/or tumor necrosis factor (TNF), each alone or in combination with corticosteroids, preferably employing recombinant human gamma interferon and/or TNF. Individuals, including adults or children, are administered amounts of these agents that are generally effective to induce the lungs of affected individuals to produce one or more surfactant components, including both phospholipid and surfactant protein substituents.